Dr Wouter Zandee provides his thoughts on the symptomatic control of functioning pancreatic NET

Video Transcript

My name is Wouter Zandee, I am an Endocrinologist at the University Medical Center Groningen.

And today I will be discussing how to reduce hormone symptoms from functioning pancreatic neuroendocrine tumours (NETs).

These functioning pancreatic NETs are rare but require specific treatment to reduce the symptoms of hypersecretion to increase quality of life.

Symptom Control

Also, symptom control is required to safely perform surgery or to treat with systemic therapy.

In general, two options exist for reduction of symptoms.

First of all reduction of tumour burden can be considered in accordance with the ENETS guidelines. This can be done with surgery, either curative or with debulking surgery or PRRT with Lu177-DOTATATE, and liver directed therapies can be effective.

Specifically, for hormone secretion several options are also available which I would like to discuss in more detail.

First line therapy is generally a somatostatin analogue (SSA) because of low toxicity and proven decreases in hormone secretion.

SSAs can also decrease glucagon secretion, which increases hypoglycemia in small numbers of patients with an insulinoma. So, for patients with an insulinoma the first administration is done clinically.

If an SSA is ineffective in controlling the hormone symptoms, PRRT with Lu177-DOTATATE is especially effective for patients with functioning pNETs. It has a symptomatic response rate of 71% and increases the quality of life for these patients.

Also everolimus can decrease hypoglycemia in patients with an insulinoma.

In case series sunitinib has been prescribed to decrease diarrhoea for patients with a VIPoma. So, these drugs can also be effective for these patients.

Conclusion

In conclusion, adequate control of symptoms is essential for patients with a functioning pNET to increase quality of life.

Generally, SSAs are first line therapy but if these prove ineffective PRRT can be especially effective in these patients.

Thank you for watching on behalf of NET CONNECT.

Dr Wouter Zandee graduated from medical school in 2010 at the Leiden University with a thesis on the surgical treatment of medullary thyroid carcinoma. Thereafter he started his training to become an internist-endocrinologist. He is currently a fellow in endocrinology at the Erasmus Medical Center, Rotterdam, focusing on several types of endocrine tumors. In the neuroendocrine tumor department he is a sub-investigator of multicenter trials. Concurrently he is pursuing a PhD on neuroendocrine tumors, focusing on biomarkers, treatment of hormonal syndromes (mainly with 177Lu-DOTATATE) and quality of care.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen, Eisai Europe Limited, ITM and Boehringer Ingelheim

Meet the experts Independent IME approved

Other programmes of interest

publication Scientific Publication
Oncology 
ADCs in HER2+ metastatic breast cancer and management of adverse events

Consensus-based guidance for clinicians and patients

Experts
Prof. Javier Cortés, Prof. Giuseppe Curigliano, Prof. Shaheenah Dawood, Dr Grażyna Suchodolska, Dr Sara Tolaney, Carla Whitbread
Endorsed by
EONS - European Oncology Nursing Society Europa Donna
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
symposium Masterclass / SymposiumVideo overview
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from the APBCS 2026 Satellite Symposium

Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients

Experts
Dr Mastura Md Yusof, Dr Hope S. Rugo, Prof. Matteo Lambertini
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jan 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs only 
patient-support Patient Support
Rare diseases 
Understanding narcolepsy

Persistent sleepiness: when to look closer

Experts
Prof. Yves Dauvilliers
Endorsed by
EU-NN ANC
eNAP
  • clock 2 MIN
  • calendar Jan 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Takeda
podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim